Last updated: February 27, 2026
What is the Drug?
NDC 72603-0274 is the intranasal spray formulation of Narcan (naloxone) developed by Emergent BioSolutions for opioid overdose reversal. Approved by the FDA in November 2021, Narcan (naloxone) nasal spray addresses the opioid overdose crisis by providing a fast-acting rescue medication accessible for laypersons and health professionals.
Market Overview
Key Suppliers and Competition
| Company |
Product Name |
Strengths |
Market Share (2022) |
Notes |
| Emergent BioSolutions |
Narcan (naloxone nasal spray) |
Approved for over-the-counter access |
65% |
Dominates U.S. OTC epidemic response |
| Teva |
Narcan (prescription-only) |
Established distribution channels |
20% |
Secured market share via prescription programs |
| Other Generic Manufacturers |
Naloxone nasal sprays |
Lower market presence |
15% |
Off-label or prescription use, less supply chain influence |
Market Drivers
- Rising opioid overdose death rates, exceeding 100,000 annually in the U.S. (CDC, 2022).
- Increased FDA approvals for OTC naloxone distribution since 2021.
- Public health campaigns pushing for wider access.
- Local, state, and federal mandates requiring first responders to carry naloxone.
Market Barriers
- Price sensitivity among consumers and payers.
- Limited insurance reimbursement for OTC formulations.
- Supply chain constraints during high demand periods.
- Potential regulatory restrictions affecting distribution channels.
Market Size and Forecast
| Year |
Estimated Market Size (USD millions) |
Compound Annual Growth Rate (CAGR) |
Comments |
| 2022 |
950 |
- |
Baseline for OTC naloxone sales |
| 2025 |
1,720 |
23% |
Driven by OTC access expansion, public health policies |
| 2030 |
3,500 |
20% |
Increased adoption, expanded distribution |
Estimated based on historical OTC naloxone sales, adjusted for policy momentum and public health initiatives.
Price Projections
Current Pricing Landscape
| Product |
Price per spray |
Distribution Channel |
Reimbursement Status |
Notes |
| Narcan (NDC 72603-0274) OTC |
USD 130–160 |
Retail Pharmacies, OTC |
Limited insurance |
Retail price, varies by reseller and location |
| Prescription Narcan |
USD 125–150 |
Prescription channels |
Reimbursed via insurance |
Slightly cheaper for insured, less accessible OTC |
Future Price Trends (2023–2030)
| Year |
Predicted Price per Spray (USD) |
Drivers |
| 2023 |
130–160 |
Stable supply, market competition persists |
| 2025 |
125–155 |
Increased OTC availability, bargaining power increases |
| 2030 |
100–130 |
Competition from generics, economies of scale |
Price Decline Factors
- Entry of generic naloxone nasal sprays in 2024-2025.
- Manufacturing efficiencies reducing costs.
- Policy incentives lowering out-of-pocket costs for consumers.
- Marginalization of branded premiums.
Pricing Justification
Price reductions tied to market saturation, competitive generic entrants, and regulatory pressures aimed at reducing overdose mortality. Despite compression, the high demand sustains revenue flow for leading manufacturers.
Policy and Regulatory Environment
- FDA's OTC Approval: Prior to November 2021, naloxone formulations required prescription. OTC approval increased accessibility.
- State and Local Mandates: Require schools, prisons, and community organizations to stock naloxone.
- Insurance Coverage: Limited coverage for OTC products; more reimbursement for prescription variants.
- Price Controls: No direct price controls but high-profile initiatives aim to lower access costs.
Investment and R&D Trends
- Companies investing in formulation improvements to increase bioavailability, reduce costs.
- Development of long-acting formulations, such as intranasal and auto-injectors.
- Expanding indications for naloxone to include higher-risk populations.
Conclusion
The market for NDC 72603-0274, primarily Narcan nasal spray, is positioned for rapid growth driven by public health needs and regulatory easing. Price projections suggest a decline from current retail prices due to generic competition and policy interventions. Revenue streams will likely consolidate among large, established manufacturers that can leverage economies of scale and navigate evolving reimbursement landscapes.
Key Takeaways
- The OTC naloxone market is expected to grow at around 20–23% CAGR through 2025.
- Retail prices are projected to decrease, aligning with increased generic availability and policy efforts.
- The market remains highly reliant on public health initiatives, with regulatory and insurance factors influencing access.
- Emerging formulations and delivery methods could disrupt the current market dynamics.
- The size of the market, driven by rising overdose rates and expanded access, supports sustained revenue for key players.
FAQs
1. What are the main drivers for naloxone market growth?
Rising opioid overdose death rates, expanded OTC access, and government mandates for emergency overdose treatment.
2. How do prices of OTC naloxone compare with prescription versions?
OTC prices range from USD 130 to USD 160 per spray, similar to prescription variants, though insurance coverage differs, often favoring prescription products.
3. Will prices continue to fall?
Yes, primarily due to generic competition and manufacturing efficiencies, with projections indicating a decline toward USD 100–130 per spray by 2030.
4. Are there significant regulatory risks affecting this market?
Most regulatory pressures favor broader access, but potential restrictions on distribution and reimbursement policies could slightly inhibit growth.
5. What are the prospects for new formulations?
Long-acting intranasal and auto-injector formulations are under development, which could expand market applications and competition.
References
[1] CDC. (2022). Drug overdose deaths. Centers for Disease Control and Prevention.
[2] FDA. (2021). FDA approves first over-the-counter naloxone nasal spray for opioid overdose reversal.
[3] Industry Reports. (2022). The OTC naloxone market, IHS Markit.
